Hematologic Malignancies

In Standard-Risk Myeloma, Two Years of Maintenance Equals Indefinite Therapy

George Padron
Oncology Care, Hematologic Malignancies, Access & Affordability, Drug Pricing & Out-of-Pocket, Managed Care, Value Based Care | Jul 23, 2026
In standard-risk myeloma without an up-front transplant, stopping lenalidomide maintenance at 2 years matched indefinite therapy on survival, with fewer harms.

A Once-Daily Tablet Joins the Ruxolitinib Franchise

George Padron
Oncology Care, Healthcare Headlines, Hematologic Malignancies | May 2, 2026
Once-daily 55 mg Jakafi XR is bioequivalent to twice-daily 25 mg Jakafi. Indications, pharmacology, and safety profile are unchanged from the original product.

Digital Symptom Monitoring in Blood Cancer Patients Cuts Hospitalizations and Costs

George Padron
Oncology Care, AI & Critical Decision Support, Remote Patient Monitoring, Digital Therapeutics, Hematologic Malignancies | Apr 20, 2026
A 1,645-patient retrospective study found ePRO-based remote therapeutic monitoring reduced infection-related ED visits 34% and hospital admissions 52%, saving nearly $1M per 1,000 patients per year.

ASH Clinical Trial Map Could Streamline Evidence for Payers

George Padron
Oncology Care, Healthcare Headlines, Clinical Guidelines & Standards, Hematologic Malignancies | Apr 17, 2026
New ASH interactive tool and companion toolkit aim to improve clinical trial quality and diversity in hematology, with implications for payer evidence needs.

Advanced Cancer Treatment Creates New Reality of Living Long-Term With Terminal Disease

George Padron
Oncology Care, Breast Cancer, Hematologic Malignancies, GU Cancers, Lung & Thoracic, GI Cancers | Aug 27, 2025
Revolutionary cancer therapies enable patients to live years with terminal disease, requiring healthcare systems to adapt chronic care models.